AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

By Nikita Chaurasia  Date: 2021-03-23

AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

The COVID-19 vaccine co-developed by AstraZeneca Plc, a British-Swedish multinational biotechnology company, and scientists at Oxford University, has reportedly passed the U.S. clinical trials with 79% effectiveness in preventing symptomatic disease in over 32,000 participants.

AstraZeneca announced that it would keep analyzing data and make relevant provisions in a bid to request emergency use authorization (EUA) in the United States in the upcoming weeks. The move, if approved by authorities, will make the vaccine available for American citizens.

The shot has already been widely administered across several European countries. The U.S. trials, however, involved a sample size study of 32,000 participants - the largest-ever number of people to be studied for the effectiveness of AstraZeneca’s COVID-19 vaccine.

The study could reinstate public confidence in the vaccine, after speculations regarding its efficacy arose following serious blood-clotting issues in a small number of individuals in Europe who received the shot, sources claimed. The trials conducted in the U.S. found no increased risk of serious blood clotting among the vaccinated population.

AstraZeneca reportedly mentioned that the vaccine had an 80% rate of efficacy among elder participants aged 65 years and above.

In the past few weeks, blood clotting fears led several European countries, such as Italy and Germany, to temporarily discontinue the use of the vaccine. However, most countries resumed its usage after European and U.K. medicine authorities reiterated the shot's effectiveness despite the rare incidences of blood clotting, which were not proven to be connected to the vaccine.

The EU regulators claimed to not have ruled out the possibility of blood clots but emphasized that the vaccine is a shield preventing severe symptoms and death and that its benefits outweigh risks.

In other news, AstraZeneca has recently cut the number of doses delivered to the EU after blaming production delays in the Netherland and Belgium. The EU had imposed export controls for coronavirus vaccines in March this year to stop a consignment of 2,50,000 doses that were to be shipped from Italy to Australia.

Source Credits –

https://www.marketwatch.com/story/astrazeneca-us-covid-vaccine-trial-79-effective-2021-03-22?link=MW_latest_news

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...